LANGHORNE, Pa., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"), a provider of advanced wound care products, today announced that company management will participate in the following investor conferences:
The 2015 RBC Capital Markets' Global Healthcare Conference in New York, New York
- David Johnson, Chief Executive Officer, and Brian Posner, Chief Financial Officer, will present on Wednesday, February 25th at 8:30 a.m. Eastern Time (ET).
The 35th Annual Cowen Health Care Conference in Boston, Massachusetts
- David Johnson, Chief Executive Officer, and Brian Posner, Chief Financial Officer, will participate in a fireside chat on Tuesday, March 3rd at 9:20 a.m. Eastern Time (ET).
Live webcasts of the conference presentation and the fireside chat will be available on the investor relations section of the Company's website at http://ir.alliqua.com. Archives of the conference webcasts will be available for replay following the events.
About Alliqua BioMedical, Inc.
Alliqua is a provider of advanced wound care solutions. Through its sales and distribution network, together with its proprietary products, Alliqua provides a suite of technological solutions to enhance the wound care practitioner's ability to deal with the challenges of healing both chronic and acute wounds.
Alliqua currently markets its line of hydrogel products for wound care under the SilverSeal® and Hydress® brands, as well as the Sorbion sachet S® and Sorbion sana® wound care products, and its TheraBond® 3D advanced dressing which incorporates the TheraBond® 3D Antimicrobial Barrier Systems technology. It also markets the advanced wound care product Biovance®, as part of its licensing agreement with Celgene Cellular Therapeutics.
In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its proprietary hydrogel technology. Alliqua's electron beam production process, located at its 16,000 square foot GMP manufacturing facility in Langhorne, PA, allows Alliqua to develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries.
CONTACT: Investor Relations: Westwicke Partners on behalf of Alliqua Biomedical, Inc. Mike Piccinino, CFA +1-443-213-0500 [email protected]